检索结果-南通市图书馆

Research on Approaches of Multidisciplinary Design Optimization for Non-hierarchic Systems

在线全文

学校读者我要写书评

暂无评论

Computer Aided Drafting,Design and Manufacturing 2000年第1期10卷 84-94页

作者： chen Baihong zhong yifang Liu jihong Xiao Renbin zhou ji (CAD Center of huazhong university of science & technology, wuhan 430074, PR.china)

In complex engineering optimization, multilevel or two-level approaches are often applied. These approaches are carried out in assumption that there are no connections among sub problems at the same level. But it is difficult to construct the models that suit to this assumption. In recent years, the complexity of engineering systems has led to the rapid development in the field of Multidisciplinary Design Optimization (MDO). In MDO, two kinds of coupled factors, coupled variables (or functions) and system (or global) variables, always exist among all disciplines. These variable5 or functions make it disordered to solve the whole system. So, how to handle these variables is one of important studies in MDO. In this paper two approaches are discussed for handling these coupled factors in non-hierarchic system in MDO. And a test engineering example gives a demonstration about the implemeniation of these approaches.

关键词： coupled factors two-level technique collaborative optimization MDO

An Automatic Generation System of Reinforcement Detail Drawings for Hydraulic Structures

在线全文

学校读者我要写书评

暂无评论

Computer Aided Drafting,Design and Manufacturing 2000年第1期10卷 41-49页

作者： Qian Yusen chen Liping zhong yifang zhou ji (National CAD Sopport Software Engineering Research Center (wuhan) huazhong university of science and technology, wuhan P. r. china, 430074) Niu Xinqiang Yang Xinjun Yang Benxin (Changjiang Water Resource C

Reinforcement detail drawings are one important part of the design of hydraulic structures and the important basis of construction and management. However, the efficiency of the traditional creation of engineering drawings is very low and the workload is heavy. There is no satisfactory software for hydraulic engineering because of the irregularity and diversity of hydraulic structures' shape. An automatic generation system of reinforcement detail drawings for hydraulic structures is introduced. Its functions and modules are introduced first. The related technologies such as automatic driensioning are discussed in detail. At the end of the paper, an example is given.

关键词： reinforcement detail drawings automatic dimensioning collision checking engineering drawings

Characterization of acute-on-chronic liver diseases: A multicenter prospective cohort study

在线全文

学校读者我要写书评

暂无评论

World Journal of Hepatology 2024年第5期16卷 809-821页

作者： Yuan-Yao Zhang Sen Luo Hai Li Shu-Ning Sun Xian-Bo Wang Xin Zheng Yan Huang Bei-Ling Li Yan-Hang Gao Zhi-Ping Qian Feng Liu Xiao-Bo Lu Jun-Ping Liu Hao-Tang Ren Yu-Bao Zheng Hua-Dong Yan Guo-Hong Deng Liang Qiao Yan Zhang Wen-Yi Gu Xiao-Mei Xiang Yi zhou Yi-Xin Hou Qun Zhang Yan Xiong Cong-Cong Zou Jun chen Ze-Bing Huang Xiu-Hua jiang Ting-Ting Qi Yuan-Yuan chen Na Gao Chun-Yan Liu Wei Yuan Xue Mei jing Li tao Li Rong-jiong Zheng Xin-Yi zhou Jun Zhao zhong-ji Meng Department of Infectious Disease Institute of Biomedical ResearchRegulatory Mechanism and Targeted Therapy for Liver Cancer Shiyan Key LaboratoryHubei provincial Clinical Research Center for Precise Diagnosis and Treatment of Liver CancerTaihe HospitalHubei University of MedicineShiyan 442000Hubei ProvinceChina Department of Gastroenterology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200120China Department of Infectious Diseases Southwest HospitalThe Third Military Medical University(Army Medical University)Chongqing 400000China Center of Integrative Medicine Beijing Ditan HospitalCapital Medical UniversityBeijing 100020China Department of Infectious Diseases Institute of Infection and ImmunologyUnion HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430020Hubei ProvinceChina Department of Infectious Diseases Hunan Key Laboratory of Viral HepatitisXiangya HospitalCentral South UniversityChangsha 110051Hunan ProvinceChina Hepatology Unit Department of Infectious DiseasesNanfang HospitalSouthern Medical UniversityGuangzhou 510515Guangdong ProvinceChina Department of Hepatology The First Hospital of Jilin UniversityChangchun 130021Jilin ProvinceChina Department of Liver Intensive Care Unit Shanghai Public Health Clinical CentreFudan UniversityShanghai 200093China Tianjin Institute of Hepatology Nankai University Second People's HospitalTianjin 300192China Infectious Disease Center The First Affiliated Hospital of Xinjiang Medical UniversityUrumqi 830054Xinjiang Uygur Autonomous RegionChina Department of Infectious Diseases and Hepatology The Second Hospital of Shandong UniversityJinan 250000Shandong ProvinceChina State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Collaborative Innovation Center for Diagnosis and Treatment of Infectious DiseaseThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310000Zhejiang ProvinceChina Department of Infectious Diseases The Thir

BACKGROUND Acute-on-chronic liver disease(AoCLD)accounts for the majority of patients hospitalized in the Department of Hepatology or Infectious *** To explore the characterization of AoCLD to provide theoretical guidance for the accurate diagnosis and prognosis of *** Patients with AoCLD from the Chinese Acute-on-Chronic Liver Failure(ACLF)study cohort were included in this *** clinical characteristics and outcomes,and the 90-d survival rate associated with each clinical type of AoCLD were analyzed,using the Kaplan-Meier method and the log-rank *** A total of 3375 patients with AoCLD were enrolled,including 1679(49.7%)patients with liver cirrhosis acute decompensation(LC-AD),850(25.2%)patients with ACLF,577(17.1%)patients with chronic hepatitis acute exacer-bation(CHAE),and 269(8.0%)patients with liver cirrhosis active phase(LC-A).The most common cause of chronic liver disease(CLD)was HBV infection(71.4%).The most common precipitants of AoCLD was bacterial infection(22.8%).The 90-d mortality rates of each clinical subtype of AoCLD were 43.4%(232/535)for type-C ACLF,36.0%(36/100)for type-B ACLF,27.0%(58/215)for type-A ACLF,9.0%(151/1679)for LC-AD,3.0%(8/269)for LC-A,and 1.2%(7/577)for *** HBV infection is the main cause of CLD,and bacterial infection is the main precipitant of *** most common clinical type of AoCLD is *** diagnosis and timely intervention are needed to reduce the mortality of patients with LC-AD or ACLF.

关键词： Acute-on-chronic liver disease Acute-on-chronic liver failure Liver cirrhosis Clinical features Prognosis

CEPC Technical Design Report

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Radiation Detection technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves Weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-Jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang Wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin chen Danping chen Fuqing chen Fusan chen Gang chen Guoming chen Hua-Xing chen Huirun chen jinhui chen ji-Yuan chen Kai chen Mali chen Mingjun chen Mingshui chen Ning chen Shanhong chen Shanzhen chen Shao-Long chen Shaomin chen Shiqiang chen Tianlu chen Wei chen Xiang chen Xiaoyu chen Xin chen Xun chen Xurong chen Ye chen Ying chen Yukai chen Zelin chen Zilin chen Gang chen Boping chen Chunhui chen Hok Chuen cheng Huajie cheng Shan cheng Tongguang cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng Wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong jianin AGH university of science and technology Faculty of Physics and Applied Computer ScienceKrakow Anhui university HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu university Institute of ScienceVaranasi Bandirma Onyedi Eylul university Bandirma Beihang university Beijing Beijing Computational science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of technology Beijing Beijing Normal university Beijing Brown university ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad university Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo university Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central china Normal university WuhanHubei Central South university ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan china academy of engineering physics MianyangSichuan china building materials academy Beijing china Center of Advanced science and technology Beijing china Institute of Atomic Energy Beijing china jiliang university HangzhouZhejiang china Nuclear Instrument CO. LTDBeijing china university of Geosciences Beijing china university of Geosciences WuhanHubei china university of Mining and technology XuzhouJiangsu china West Normal university NanchongSichuan Chongqing university Department of PhysicsChongqing Chulalongkorn university Bangkok City university of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell university IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu university DalianLiaoning Dalian university of technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP jiNR) Dubna East china university Of science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by china,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan Shan Xu-Yong Wei Rui Wang Chang-Ku jia Li Zhuang Tian Shen Li-Min Ding Zhi-Dan Xu Lai-Bang Luo Li-Bo Sun Guang-Ming Li Tai-Shi Fang Nan jiang Kun Zhang Zhao-jie Su Zhi-Hai Peng Ren Lang tao jiang Qiang He Lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi Guo Liu-Gen Lan Xu-Yong Sun Dong chen Zhi-Shui chen Da-Wei zhou Shao-Jun Ye Qi-Fa Ye Min Tian jian-Hua Shi Bo Wang jiang Liu Qian Lu Wei Rao jin-Zhen Cai tao Lv jia-Yin Yang Pu-Sen Wang Lin zhong jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu Chang-jiang Lu Cai-De Lu Dong-Hua Zhang Xuan Wang Zi-Qiang Li Mu-jian Teng Jun-jie Li Wen-tao jiang jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-Hua Song Zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song ji-zhou Wang Zheng Wang jian zhou Gang chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-jie Luo zhong-zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of wuhan university Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in china

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2022年第31期28卷 4417-4430页

作者： Zi-Xuan Shen Dan-Dan Wu jie Xia Xian-Bo Wang Xin Zheng Yan Huang Bei-Ling Li zhong-ji Meng Yan-Hang Gao Zhi-Ping Qian Feng Liu Xiao-Bo Lu jia Shang Hua-Dong Yan Yu-Bao Zheng Wen-Yi Gu Yan Zhang jian-Yi Wei Wen-Ting Tan Yi-Xin Hou Qun Zhang Yan Xiong Cong-Cong Zou Jun chen Ze-Bing Huang Xiu-Hua jiang Sen Luo Yuan-Yuan chen Na Gao Chun-Yan Liu Wei Yuan Xue Mei jing Li tao Li Xin-Yi zhou Guo-Hong Deng jin-Jun chen Xiong Ma Hai Li Department of Gastroenterology Renji HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200127China Shanghai Institute of Digestive Disease Key Laboratory of Gastroenterology and HepatologyChinese Ministry of HealthShanghai Jiao Tong UniversityShanghai 200001China Department of Infectious Diseases Southwest HospitalThe Third Military Medical University(Army Medical University)Chongqing 400038China Center of Integrative Medicine Beijing Ditan HospitalCapital Medical UniversityBeijing 100102China Department of Infectious Diseases Institute of Infection and ImmunologyUnion HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022Hubei ProvinceChina Department of Infectious Diseases Hunan Key Laboratory of Viral HepatitisXiangya HospitalCentral South UniversityChangsha 410008Hunan ProvinceChina Hepatology Unit Department of Infectious DiseasesNanfang HospitalSouthern Medical UniversityGuangzhou 510515Guangdong ProvinceChina Department of Infectious Disease Taihe HospitalHubei University of MedicineShiyan 430418Hubei ProvinceChina Department of Hepatology The First Hospital of Jilin UniversityChangchun 130031Jilin ProvinceChina Department of Liver Intensive Care Unit Shanghai Public Health Clinical CentreFudan UniversityShanghai 201508China Tianjin Institute of Hepatology Nankai University Second People’s HospitalTianjin 300102China Department of Infectious Diseases and Hepatology The Second Hospital of Shandong UniversityJinan 250033Shandong ProvinceChina Infectious Disease Center The First Affiliated Hospital of Xinjiang Medical UniversityUrumqi 830054XinjiangChina Department of Infectious Diseases Henan Provincial People’s HospitalZhengzhou 450003Henan ProvinceChina Department of Infectious Diseases Hwamei HospitalThe Second Hospital of NingboUniversity of Chinese Academy of SciencesNingbo 315153Zhejiang ProvinceChina Department of Infectious Diseases The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 5

BACKGROUND Autoimmune liver disease(AILD)has been considered a relatively uncommon disease in china,epidemiological data for AILD in patients with cirrhosis and acute decompensation(AD)is *** To investigate the prevalence,outcome and risk factors for AILD in cirrhotic patients complicated with AD in *** We collected data from patients with cirrhosis and AD from two prospective,multicenter cohorts in hepatitis B virus endemic *** were regularly followed up at the end of 28-d,90-d and 365-d,or until death or liver transplantation(LT).The primary outcome in this study was 90-d LTfree ***-on-chronic liver failure(ACLF)was assessed on admission and during 28-d hospitalization,according to the diagnostic criteria of the European Association for the Study of the Liver(EASL).Risk factors for death were analyzed with logistic regression *** In patients with cirrhosis and AD,the overall prevalence of AILD was 9.3%(242/2597).Prevalence of ACLF was significantly lower in AILD cases(14%)than those with all etiology groups with cirrhosis and AD(22.8%)(P china,among which PBC was the m

关键词： Prevalence Autoimmune liver disease Cirrhosis and acute decompensation Mortality Acuteon-chronic liver failure

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2020年第3期7卷 249-282页

作者： Ying-Hui jin Qing-Yuan Zhan Zhi-Yong Peng Xue-Qun Ren Xun-tao Yin Lin Cai Yu-Feng Yuan ji-Rong Yue Xiao-Chun Zhang Qi-Wen Yang jianguang ji jian Xia Yi-Rong Li Fu-Xiang zhou Ya-Dong Gao Zhui Yu Feng Xu Ming-Li Tu Li-Ming Tan Min Yang Fang chen Xiao-Ju Zhang Mei Zeng Yu Zhu Xin-Can Liu jian Yang Dong-Chi Zhao Yu-Feng Ding Ning Hou Fu-Bing Wang Hao chen Yong-Gang Zhang Wei Li Wen chen Yue-Xian Shi Xiu-Zhi Yang Xue-Jun Wang Yan-Jun zhong Ming-Juan Zhao Bing-Hui Li Lin-Lu Ma Hao Zi Na Wang Yun-Yun Wang Shao-Fu Yu Lu-Yao Li Qiao Huang Hong Weng Xiang-Ying Ren Li-Sha Luo Man-Ru Fan Di Huang Hong-Yang Xue Lin-Xin Yu jin-Ping Gao Tong Deng Xian-tao Zeng Hong-Jun Li Zhen-Shun cheng Xiao-Mei Yao Xing-Huan Wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

在线全文

学校读者我要写书评

暂无评论

肺癌适应性治疗中国专家共识

循证医学 2024年第4期24卷 193-200页

作者：吴一龙陆舜程颖周清张嘉涛潘燚汪斌超韩宝惠陈海泉周清华王绿化陈明王洁周彩存刘晓晴马智勇黄诚宋启斌莫树锦钟文昭朱正飞宋勇陈蓉蓉陈克终刘基巍杨帆胡晓桦胡毅杨懿岳东升王群赵军范江陈椿孟庆威闫小龙董晓荣朱波邢力刚李兆澄李子明褚倩陈元林根段建春田攀文范云刘安文刘慧刘哲峰杨农汪步海张同梅信涛刘思阳王志杰马锐于起涛林劼涂海燕姚煜赵明芳王慧娟张海波蔡尚立张绪超李慧杜瀛瀛吴芳严令华崔久嵬王燕邬麟周建娅汪笑男黄媚娟冯卫能周进李力中国抗癌协会肺癌专业委员会广东省临床试验协会/中国胸部肿瘤研究协作组广东省肺癌研究所南方医科大学附属广东省人民医院(广东省医学科学院)广州510080 上海交通大学医学院附属胸科医院上海200030 吉林省肿瘤医院长春130021 复旦大学附属肿瘤医院上海200032 四川大学华西医院成都610041 中国医学科学院肿瘤医院深圳医院广东深圳518116 中山大学肿瘤防治中心广州510060 中国医学科学院肿瘤医院北京100021 同济大学附属上海市肺科医院上海200433 解放军总医院第五医学中心北京100039 郑州大学附属肿瘤医院/河南省肿瘤医院郑州450003 福建省肿瘤医院福州350011 武汉大学人民医院肿瘤中心武汉430060 香港中文大学医学院中国香港东部战区总医院南京210002 北京吉因加科技有限公司北京102206 北京大学人民医院北京100044 大连医科大学附属第一医院辽宁大连116011 广西医科大学第一附属医院南宁530020 解放军总医院北京100071 成都市第三人民医院/西南交通大学医学院成都610031 天津医科大学肿瘤医院天津300060 复旦大学附属中山医院上海200032 北京大学肿瘤医院北京100142 上海交通大学附属上海市第一人民医院上海200025 福建医科大学附属协和医院福州350001 哈尔滨医科大学附属肿瘤医院哈尔滨150081 空军军医大学唐都医院西安710038 华中科技大学同济医学院附属协和医院武汉430022 陆军军医大学第二附属医院-新桥医院重庆400037 山东省肿瘤医院济南250117 华中科技大学同济医学院附属同济医院武汉430030 中国医学科学院肿瘤医院山西医院太原030013 中国科学院大学附属肿瘤医院/浙江省肿瘤医院杭州310022 南昌大学附属第二医院南昌330006 湖南省第二人民医院长沙410035 南京大学医学院附属苏北人民医院江苏扬州225001 首都医科大学附属北京胸科医院北京101149 哈尔滨医科大学附属第二医院哈尔滨150001 暨南大学附属第一医院广州510630 辽宁省肿瘤医院沈阳110042 广西医科大学附属肿瘤医院南宁530012 昆明医科大学第二附属医院昆明650101 西安交通大学第一附属医院西安710061 中国医科大学附属第一医院沈阳110001 广东省中医院广州510120 广州燃石医学检验所有限公司广州510300 安徽医科大学第一附属医院合肥230022 中南大学湘雅二医院长沙410011 上海桐树生物科技有限公司上海200444 吉林大学白求恩第一医院长春130021 湖南省肿瘤医院长沙410013 浙江大学医学院附属第一医院杭州310031 南京世和基因生物技术股份有限公司南京210032 佛山市第一人民医院广东佛山528000 四川省肿瘤医院成都610042 陆军军医大学大坪医院重庆400042 不详

由中国抗癌协会肺癌专业委员会和广东省临床试验协会/中国胸部肿瘤研究协作组主办的“第21届中国肺癌高峰论坛”于2024年3月2日在广州顺利召开。此次论坛以肺癌适应性治疗为主题,从肺癌适应性治疗定义、早中晚期临床应用以及生物标志物... 详细信息

由中国抗癌协会肺癌专业委员会和广东省临床试验协会/中国胸部肿瘤研究协作组主办的“第21届中国肺癌高峰论坛”于2024年3月2日在广州顺利召开。此次论坛以肺癌适应性治疗为主题,从肺癌适应性治疗定义、早中晚期临床应用以及生物标志物对适应性治疗的指导价值等角度展开探讨并达成了专家共识。

关键词：肺癌适应性治疗共识

在线全文

学校读者我要写书评

暂无评论

全球性公共卫生危机治理:趋势与重点

管理科学学报 2021年第8期24卷 133-146页

作者：张辉刘远立陈春花陈宏民韩传峰王红卫刘兴华吕欣周涛吕孝礼陈育德王耀刚毛基业杨维中侯世科孟令鹏张维李磊胡业飞清华大学公共安全研究院北京100084 北京协和医学院公共卫生学院北京100730 北京大学国家发展研究院北京100871 上海交通大学安泰经济与管理学院上海200030 同济大学可持续发展与新型城镇化智库上海200092 华中科技大学管理学院武汉430074 国防科技大学系统工程学院长沙410073 电子科技大学大数据研究中心成都611731 清华大学公共管理学院北京100084 北京大学医学部公共卫生学院北京100083 天津医科大学天津300052 中国人民大学商学院北京100872 北京协和医学院北京100730 天津大学灾难医学研究院天津300072 上海海事大学中国(上海)自贸区供应链研究院上海201306 天津大学管理与经济学部天津300072 复旦大学国际关系与公共事务学院上海200433

全球性公共卫生危机源于突发的全球重大公共卫生事件,不确定性和复杂性特征突出,对世界经济与社会发展具有长期影响,应对这一危机则是跨时域、跨地域、跨领域的一项系统工程.揭示全球性公共卫生危机的形成机理、演化规律、治理策略,探... 详细信息

全球性公共卫生危机源于突发的全球重大公共卫生事件,不确定性和复杂性特征突出,对世界经济与社会发展具有长期影响,应对这一危机则是跨时域、跨地域、跨领域的一项系统工程.揭示全球性公共卫生危机的形成机理、演化规律、治理策略,探究相应的危机预防与处置方法、多元主体的合作网络构建方式、危机联防联控措施与应对标准规范等内容,具有重要理论意义和应用价值.现有研究已在构建整体性应急治理体系、增强政府危机决策能力、促进多元主体协调共治及技术赋能公共卫生危机治理等方面实现了一定的知识积累.未来,中国管理科学应继续围绕全球性公共卫生危机的影响因素、形成机理及演化规律,应急资源供应与分配管理,多元主体参与机制及其行为规律,后危机时代的企业管理以及加强国际传播能力建设等问题展开学术探索.

关键词：公共卫生危机危机管理应急管理国家战略